GlassScriptPhysician profile
Mackenzi Heaton
NPI 1811657034
$11,519.71
in general payments reported to CMS, 2019-2025
64 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,907 · 2023: $4,047 · 2024: $2,344 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,184 · Education: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,184.03 |
| Education | $428.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $832.23 | 2022-2025 | Opdivo, Opdualag |
| Pfizer INC. | $642.55 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $601.57 | 2023-2025 | |
| Daiichi Sankyo INC. | $557.17 | 2022-2025 | Enhertu, Datroway, Vanflyta |
| Janssen Biotech, INC. | $557.09 | 2022-2025 | Erleada, Rybrevant, Carvykti |
| Astrazeneca Pharmaceuticals LP | $554.48 | 2022-2025 | Enhertu, Imfinzi |
| Celgene Corporation | $542.23 | 2022-2024 | Reblozyl, Sprycel |
| Lilly USA, LLC | $388.51 | 2022-2024 | Verzenio |
| Merck Sharp & Dohme LLC | $336.20 | 2022-2025 | Keytruda, Lynparza |
| Genzyme Corporation | $334.69 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $316.78 | 2022-2023 | |
| Glaxosmithkline, LLC. | $316.15 | 2022-2024 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $310.57 | 2022-2025 | Iclusig, Ninlaro |
| Genentech USA, INC. | $297.23 | 2022-2024 | Tecentriq, Alecensa, Rozlytrek |
| Exelixis INC. | $277.19 | 2022-2024 | Cabometyx |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $268.41 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $261.77 | 2022-2023 | Imbruvica |
| Seagen INC. | $251.04 | 2022-2023 | Padcev, Adcetris |
| Bayer Healthcare Pharmaceuticals INC. | $226.68 | 2022-2024 | |
| Eisai INC. | $223.26 | 2022-2024 | |
| Astellas Pharma US INC | $211.27 | 2023-2024 | Cresemba |
| Gilead Sciences, INC. | $200.98 | 2023-2025 | Trodelvy |
| G1 Therapeutics, INC. | $186.35 | 2022 | |
| Amgen INC. | $185.88 | 2022-2023 | Blincyto, Kyprolis, Nplate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.05 | 2022-2024 | Gilotrif |
| Incyte Corporation | $180.82 | 2022-2024 | Monjuvi, Pemazyre |
| Sanofi-Aventis U.S. LLC | $172.67 | 2022-2024 | |
| Agios Pharmaceuticals, INC. | $142.50 | 2022 | |
| Beigene USA, INC. | $128.45 | 2022-2024 | Brukinsa |
| Pharmaessentia USA Corporation | $123.06 | 2023 | Besremi |
| Aveo Pharmaceuticals, INC. | $115.68 | 2022-2023 | Fotivda |
| Tempus Ai, INC | $114.33 | 2024 | |
| Myriad Genetic Laboratories, INC. | $104.24 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $97.78 | 2023-2024 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $94.40 | 2023 | Epkinly, Imbruvica |
| Array Biopharma INC | $86.42 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Sobi, INC | $86.09 | 2022-2023 | |
| Cti Biopharma Corp. | $80.57 | 2023 | Vonjo |
| Emd Serono, INC. | $72.36 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $70.99 | 2022-2023 | Oxlumo |
| Tersera Therapeutics LLC | $65.75 | 2022-2023 | Xermelo |
| Acrotech Biopharma INC. | $55.48 | 2023-2024 | Beleodaq, Folotyn |
| Pharmacosmos Therapeutics INC. | $54.64 | 2022-2023 | Monoferric |
| Taiho Oncology, INC. | $51.15 | 2022 | |
| Servier Pharmaceuticals LLC | $42.71 | 2022-2023 | |
| Adaptive Biotechnologies Corporation | $41.09 | 2023-2025 | Clonoseq |
| Sumitomo Pharma America, INC. | $40.35 | 2023 | Orgovyx |
| Morphosys, US INC. | $36.87 | 2023 | Monjuvi |
| Fresenius Kabi USA, LLC | $36.13 | 2024 | Stimufend |
| Heron Therapeutics, INC. | $35.57 | 2022 | |
| Immunocore Limited | $33.45 | 2024 | Kimmtrak |
| Eusa Pharma (US) LLC | $33.08 | 2022 | |
| Kite Pharma, INC. | $30.85 | 2023 | |
| Stryker Corporation | $30.80 | 2023 | Spy-Phi System |
| Stemline Therapeutics INC. | $25.00 | 2025 | Orserdu |
| Accord Healthcare, INC. | $24.88 | 2024 | |
| Deciphera Pharmaceuticals INC. | $23.58 | 2022 | |
| Foundation Medicine, INC. | $22.27 | 2022 | |
| Ethicon US, LLC | $19.57 | 2025 | Vistaseal, Ethicon, Stratafix |
| Fennec Pharmaceuticals, INC. | $19.46 | 2024 | Pedmark |
| Coherus Oncology, INC. | $18.02 | 2025 | Loqtorzi |
| Telix Pharmaceuticals | $17.26 | 2024 | Illuccix |
| Myovant Sciences INC. | $16.08 | 2022 | |
| Puma Biotechnology, INC. | $13.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzi Heaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.